# 04_QA_REPORT — PP-0184: CLDN18.2 Testing

## 1. Identity

| Field | Value |
|---|---|
| QA Report ID | QA-PP-0184 |
| PP ID | PP-0184 |
| Title | CLDN18.2 Testing for Gastric Adenocarcinoma |
| Version | 1.0.0 |
| QA Mode | Gold Population Package QA |
| Evidence Basis | Project Source Files |
| Last Updated | 2026-08-09 |
| Final Status | PASS — GOLD — READY FOR INTEGRATION |

---

# 2. QA Scope

This report evaluates the complete PP-0184 Gold package:

1. `01_CKO.md`
2. `02_KNOWLEDGE_PASSPORT.md`
3. `03_PRIMARY_EVIDENCE_PACKAGE.md`
4. `04_QA_REPORT.md`

The package was evaluated against:

- CORE_WORKING_RULES v1.6;
- FREEZE GOLD POPULATION PACKAGE SPECIFICATION v1.0;
- approved PP-0184 Decision Batch;
- project Source Files;
- approved Gold discussion/artifact depth conventions.

The absolute full-depth rule was applied:

> **The package must be at least as deep as the approved Gold references; it must not be compacted, abbreviated, or made shallower.**

---

# 3. Layer 1 — Content QA

## 3.1 Scope respected

### PASS

The package remains focused on:

> **CLDN18.2 Testing for Gastric Adenocarcinoma**

It does not convert the PP into a general CLDN18.2 biology or zolbetuximab treatment package.

---

## 3.2 Clinical question answered

### PASS

The package answers:

- what CLDN18.2 is;
- why it is tested;
- who should be tested;
- when testing is relevant;
- what tissue is used;
- how IHC is used;
- what positive and negative mean;
- why the result matters clinically;
- what limitations exist.

---

## 3.3 Completeness

### PASS

Required foundational domains are present:

- definition;
- purpose;
- indication;
- timing;
- specimen;
- method;
- interpretation;
- threshold;
- clinical relevance;
- biomarker integration;
- misconceptions;
- limitations;
- evidence hierarchy;
- Knowledge Graph;
- boundary.

---

## 3.4 Internal consistency

### PASS

The package consistently uses:

- CLDN18.2;
- IHC;
- membranous staining;
- 2+/3+;
- ≥75% viable tumor cells.

No conflicting threshold or alternate definition was introduced.

---

## 3.5 Depth

### PASS — ABSOLUTE FULL-DEPTH RULE

The package is deliberately non-compacted.

The CKO includes:

- metadata;
- objectives;
- scope;
- extensive clinical knowledge blocks;
- patient explanation;
- clinical importance;
- key concepts;
- misconceptions;
- evidence classification;
- clinical-use model;
- Knowledge Graph;
- revision history.

The Knowledge Passport includes:

- identity;
- classification;
- patient journey;
- runtime use;
- retrieval metadata;
- graph;
- clinical scope;
- authoritative sources;
- evidence classification;
- governance metadata;
- version control;
- change history;
- final status.

The Evidence Package includes:

- clinical question;
- educational intent;
- scope;
- primary/supporting sources;
- hierarchy;
- evidence matrix;
- evidence notes;
- trial evidence;
- claims summary;
- consistency review;
- evidence gaps;
- update triggers;
- source traceability;
- boundary verification;
- final evidence status.

### Depth conclusion

**No compaction detected.**

---

# 4. Layer 2 — Clinical QA

## 4.1 Guideline concordance

### PASS

The core testing definition is aligned with NCCN Gastric Cancer v2.2026:

- untreated;
- inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma;
- zolbetuximab being considered;
- biopsy or surgical specimen;
- IHC;
- ≥75% viable tumor cells;
- moderate-to-strong membrane staining;
- 2+ or 3+ intensity.

---

## 4.2 Threshold accuracy

### PASS

The package preserves the compound nature of the positivity criterion.

It does not simplify positivity to:

> “high CLDN18.2 expression.”

It correctly preserves:

> **percentage + membrane localization + intensity.**

---

## 4.3 Negative-result interpretation

### PASS

The package correctly distinguishes:

> **below clinical positivity threshold**

from:

> **complete biological absence of CLDN18.2**.

No unsupported inference is made.

---

## 4.4 Treatment-context accuracy

### PASS

The package correctly explains that CLDN18.2 testing is relevant because of CLDN18.2-directed treatment, particularly zolbetuximab.

It does not claim:

> positive = automatic treatment.

---

## 4.5 Biomarker integration

### PASS

The package correctly maintains separation between:

- CLDN18.2;
- HER2;
- PD-L1;
- MSI/MMR.

It does not infer one biomarker from another.

---

## 4.6 Prevalence

### PASS

The package presents 24%–38% as an approximate contextual range and preserves NCCN's warning that prevalence varies with:

- detection method;
- assay;
- positivity definition.

No fixed universal prevalence is invented.

---

## 4.7 Histologic association

### PASS

Diffuse-subtype association is presented as an association, not as a diagnostic substitute.

---

## 4.8 EBV

### PASS

The package explicitly preserves the uncertainty of the CLDN18.2/EBV relationship.

No clinical rule is invented.

---

## 4.9 Safety

### PASS

No individualized diagnosis or treatment instruction is provided.

The package explicitly redirects individualized treatment decisions to the clinical team.

---

# 5. Layer 3 — Educational QA

## 5.1 Patient-friendly structure

### PASS

The package uses:

- short sections;
- one concept per block;
- defined terminology;
- explanatory language;
- patient-facing examples;
- misconception correction.

---

## 5.2 Terminology

### PASS

Terms such as:

- CLDN18.2;
- IHC;
- membranous staining;
- viable tumor cells;
- 2+/3+;
- biomarker;

are explained in context.

---

## 5.3 Logical flow

### PASS

The knowledge sequence follows:

**What is CLDN18.2?**

↓

**Why test it?**

↓

**Who/when?**

↓

**What specimen?**

↓

**How is it tested?**

↓

**How is it interpreted?**

↓

**What does positive/negative mean?**

↓

**Why does it matter for treatment?**

↓

**How does it relate to other biomarkers?**

↓

**What are the limitations?**

---

## 5.4 Misconception handling

### PASS

The package explicitly addresses high-risk misconceptions including:

- gene mutation versus protein expression;
- blood test versus tissue test;
- any staining versus formal positivity;
- 75% of slide versus viable tumor cells;
- strong staining alone;
- negative versus absent;
- positive versus automatic treatment;
- CLDN18.2 versus HER2;
- CLDN18.2 versus PD-L1;
- CLDN18.2 versus MSI/MMR;
- histology versus direct testing.

---

## 5.5 No overclaiming

### PASS

The package avoids:

- universal testing language;
- unsupported prognostic claims;
- unsupported EBV rules;
- automatic treatment language;
- invented retesting intervals;
- invented assay-performance statistics.

---

# 6. Layer 4 — Governance QA

## 6.1 Four-artifact structure

### PASS

Exactly four required artifacts are present:

- `01_CKO.md`
- `02_KNOWLEDGE_PASSPORT.md`
- `03_PRIMARY_EVIDENCE_PACKAGE.md`
- `04_QA_REPORT.md`

---

## 6.2 Specification compliance

### PASS

The package follows the locked Gold Population Package Specification.

No alternative artifact architecture was introduced.

---

## 6.3 Source-first compliance

### PASS

The package is grounded in the project Source Files.

The principal current source is:

> `1. Gastric Cancer_v.2.2026_NCCN-3-109.pdf`

with NCI PDQ and other project sources used as supporting evidence.

---

## 6.4 Evidence traceability

### PASS

Major clinical claims are mapped to source materials in the Evidence Matrix and Source Traceability section.

---

## 6.5 Knowledge Graph

### PASS

The package declares:

- prerequisite PPs;
- related PPs;
- downstream specialized packages.

The architecture preserves the CLDN18.2 branch without absorbing adjacent package ownership.

---

## 6.6 Boundary

### PASS

The final boundary is clean, compact, ownership-oriented and non-duplicative.

It distinguishes:

- Core;
- Supporting;
- Explicitly Excluded;
- Delegated-to PP.

---

## 6.7 Versioning

### PASS

Version:

**1.0.0**

is appropriate for initial Gold production.

---

## 6.8 Repository readiness

### PASS

Artifact names follow the governed four-artifact convention.

The package is ready for integration.

---

# 7. Boundary QA

## Core

CLDN18.2 testing purpose, clinical indication, specimen, IHC assessment, membranous staining, 2+/3+ intensity, ≥75% viable-tumor-cell threshold, positive/negative interpretation, and treatment-selection relevance.

## Supporting

Prevalence, histologic context, biomarker relationships, heterogeneity, EBV uncertainty, and randomized evidence explaining treatment relevance.

## Explicitly Excluded

Detailed CLDN18.2 biology, laboratory IHC methodology, detailed scoring/adjudication, drug management, individualized treatment, and other biomarker methodologies.

## Delegated-to PP

CLDN18.2 Biology; CLDN18.2 IHC Testing; CLDN18.2 Scoring; CLDN18.2-targeted Therapy; Zolbetuximab; Companion Diagnostics; PP-0181 HER2 Testing; PP-0182 MSI/MMR Testing; PP-0183 PD-L1 Testing.

### Boundary verdict

**PASS — no material overlap or ownership conflict identified.**

---

# 8. Final QA Checklist

| QA Item | Status |
|---|---|
| Correct PP identity | PASS |
| Correct title | PASS |
| Approved scope preserved | PASS |
| Full-depth rule satisfied | PASS |
| No compaction | PASS |
| Four required artifacts | PASS |
| CKO complete | PASS |
| Knowledge Passport complete | PASS |
| Evidence Package complete | PASS |
| QA Report complete | PASS |
| NCCN v2.2026 used as controlling current guideline | PASS |
| IHC criterion accurate | PASS |
| ≥75% threshold accurate | PASS |
| 2+/3+ intensity accurate | PASS |
| Specimen context accurate | PASS |
| Testing indication accurate | PASS |
| Treatment context accurate | PASS |
| No unsupported clinical claims | PASS |
| Evidence gaps disclosed | PASS |
| Boundary declared | PASS |
| Knowledge Graph declared | PASS |
| Versioning compliant | PASS |
| Repository-ready structure | PASS |

---

# 9. Final Decision

# PASS

### Content QA

**PASS**

### Clinical QA

**PASS**

### Educational QA

**PASS**

### Governance QA

**PASS**

---

# 10. Final Status

**QA final status: PASS — GOLD — READY FOR INTEGRATION.**
